Tag: TROP2
Results of Preclinical Data for GQ1010 Confirm Potential for Best-In-Class TROP2-Targeted...
The trophoblast cell surface antigen 2 (TROP2), a transmembrane glycoprotein that plays a role in cell self-renewal, proliferation, and transformation and survival, is overexpressed in many forms of cancers independent of baseline levels of TROP2 expression.
Daiichi Sankyo and AstraZeneca Sign Collaboration with Lung Cancer Research Foundation;...
The Lung Cancer Research Foundation (LCRF), a leading nonprofit organization focused on funding innovative, high-reward research with the potential to extend survival and improve...
Combinations with Datopotamab Deruxtecan Show Promising Clinical activity in Treatment of...
Initial results from the TROPION-Lung02 Phase Ib trial demonstrated that that datopotamab deruxtecan (Dato-DXd), a specifically designed TROP2-directed DXd antibody drug conjugate (ADC) being...
Kelun-Biotech Signs Oncology Research Collaboration Agreement with Merck/MSD
Chinese clinical-stage biotech company Kelun-Biotech*, a subsidiary of Sichuan Kelun Pharmaceutical, has signed an exclusive license agreement with Merck & Co/MSD to develop an...
Sacituzumab Govitecan Increases PFS for Patients With Most Common Type of...
Treatment with sacituzumab govitecan (Trodelvy®; Gilead Sciences), an antibody-drug conjugate (ADC), resulted in longer progression-free survival (PFS) compared to physician’s choice of chemotherapy in...
ESMO 2020: Late-Breaking Data for HER3 Directed ADC Patritumab Deruxtecan in...
Data for patritumab deruxtecan (U3-1402; Daiichi Sankyo) and fam-trastuzumab deruxtecan-nxki* (Enhertu®; Daiichi Sankyo/AstraZeneca), two antibody-drug conjugates (ADC) based on Daiichi Sankyo's proprietary DXd ADC...
Daiichi Sankyo and AstraZeneca Agree on Global Development and Commercialization for...
Daiichi Sankyo and AstraZeneca confirmed entering into a global development and commercialization agreement for datopotamab deruxtecan also know as DS-1062, a TROP2 directed DXd...
ASCO 2020 – Advancing Antibody-drug Conjugates: Sacituzumab Govitecan
With a growing number of antibody-drug conjugates being approved by regulatory agencies around the world and promising clinical benefits seen in investigational agents, the...
Everest Medicines to Initiate a Registration Study in China for Sacituzumab...
China-based Everest Medicines, a biopharmaceutical company focused on developing and commercializing transformative products, address critical unmet medical needs for patients in Greater China and...
Rapid Advances in the Development of Novel ADCs Targeting B7-H3 and...
With five antibody-drug conjugates (ADC) having received approval from the United States Food and Drug Administration (FDA) and other regulators around the world and...
